ClinicalTrials.gg
RecruitingNCT07539298VALORIA-PilotUpdated Aug 20, 2026

Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot

A Phase 2/3 interventional study of Valsartan and Placebo in Atrial Functional Mitral Regurgitation, sponsored by Jonathan Beaudoin. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Jonathan Beaudoin · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Mitral Valve Insufficiency with a site in Canada — 10 open to participants now, 23 under way, 1 of them phase 3. Mitral Valve Insufficiency · Canada.

Planned enrollment
26th of 35
50 · median 130
Started
2026
with 1 other
Phase 2/3
2 of 47
1 open now
Primary completion
2029-05
later than 17 of 22 live
Registered
47th of 47
by date
Lead sponsor
1 of 47
Jonathan Beaudoin

Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, this one is the 26th largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 17 of the 22 other live ones, and was the 47th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

10 of the 47 studies in Mitral Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Mitral Valve Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether valsartan can slow the progression of atrial functional mitral regurgitation (AFMR) in adults with preserved left ventricular ejection fraction. The study will also evaluate the safety and tolerability of valsartan in this population.

The main questions it aims to answer are:

  • Does treatment with valsartan reduce the progression of atrial functional mitral regurgitation compared with placebo?
  • Does valsartan have favorable effects on mitral valve leaflet remodeling and related cardiac structure and function?
  • Is valsartan safe and well tolerated in patients with atrial functional mitral regurgitation who do not currently require angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?

Researchers will compare valsartan to a placebo (a look-alike substance with no active drug) to see if valsartan reduces the progression of atrial functional mitral regurgitation and improves clinical and imaging outcomes.

Participants will:

  • Take valsartan or placebo twice daily for 12 months, with dose adjustments based on blood pressure, kidney function, and tolerance
  • Undergo 3D echocardiography at baseline, 6 months, and 12 months
  • Complete a 6-minute walk test at baseline and 12 months
  • Complete the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 6 months, and 12 months
  • Undergo 24-hour ambulatory blood pressure monitoring at 1 month
  • Have regular safety monitoring, including phone follow-up at 7 days, blood tests at 1 month, and blood pressure checks after dose adjustments
Read the detailed description

Atrial functional mitral regurgitation (AFMR) is a common and increasingly recognized condition, particularly among older adults, women, patients with atrial fibrillation, and those with heart failure with preserved ejection fraction (HFpEF). AFMR is associated with significant morbidity and mortality, including recurrent hospitalizations and reduced quality of life. Current treatment options remain limited and are mainly focused on managing symptoms and associated conditions, with no therapy specifically targeting the underlying mechanisms of AFMR progression.

The pathophysiology of AFMR is characterized by left atrial dilation, which leads to stretching of the mitral annulus and inadequate leaflet adaptation in the absence of significant left ventricular dilation or systolic dysfunction. Although mitral valve leaflets have the capacity to adapt by increasing their surface area in response to annular dilation, this compensatory mechanism is often insufficient, resulting in progressive mitral regurgitation. Experimental and observational data suggest that activation of the renin-angiotensin-aldosterone system may contribute to maladaptive leaflet remodeling, fibrosis, and thickening.

Angiotensin receptor blockers (ARBs) have been shown in preclinical and observational studies to reduce fibrosis and promote more favorable tissue remodeling in cardiac structures, including valvular tissue. However, the potential role of ARBs in slowing the progression of AFMR has not been specifically evaluated in a randomized clinical trial. Valsartan, a commonly used ARB, may promote more adequate mitral leaflet adaptation and reduce structural maladaptive changes, thereby limiting AFMR progression.

The VALORIA study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of valsartan on the progression of AFMR.

The study will enroll 50 adult participants with at least moderate atrial functional mitral regurgitation, a left ventricular ejection fraction of 50% or greater, and no current indication for treatment with angiotensin-converting enzyme inhibitors or ARBs.

Participants will be randomized in a 1:1 ratio to receive either valsartan or placebo for a total duration of 12 months.

Participants assigned to the active treatment arm will receive valsartan at an initial dose of 40 mg twice daily, with planned titration up to a maximum of 160 mg twice daily based on tolerance, blood pressure, renal function, and potassium levels. Participants in the placebo group will follow an identical dosing and titration schedule. Dose adjustments will be guided by a standardized follow-up algorithm and predefined safety criteria, including hypotension, worsening renal function, or hyperkalemia.

All participants will undergo a comprehensive clinical and imaging evaluation at baseline. Three-dimensional transthoracic echocardiography will be performed at baseline, 6 months, and 12 months to assess mitral regurgitation severity, mitral annular geometry, and mitral leaflet morphology. Functional capacity will be evaluated using the 6-minute walk test at baseline and at 12 months. Health-related quality of life will be assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 6 months, and 12 months.

Blood pressure will be monitored regularly throughout the study, including 24-hour ambulatory blood pressure monitoring at 1 month. Safety assessments will include a telephone follow-up at 7 days after treatment initiation, laboratory testing (serum creatinine and electrolytes) at 1 month, and additional blood pressure measurements after each dose adjustment.

The primary objective of the VALORIA study is to determine whether treatment with valsartan reduces the progression of atrial functional mitral regurgitation compared with placebo over a 12-month period. Secondary objectives include evaluating the effects of valsartan on mitral valve leaflet remodeling, cardiac structure and function, exercise capacity, and quality of life, as well as assessing the safety and tolerability of valsartan in this patient population.

By specifically targeting the structural mechanisms underlying AFMR, the VALORIA study aims to provide novel evidence to support a disease-modifying pharmacologic approach for this common and clinically significant condition.

03

Conditions studied

  • Atrial Functional Mitral Regurgitation

Keywords

  • mitral regurgitation
  • Atrial functional mitral regurgitation
  • valsartan
  • placebo
  • mitral valve leaflets
  • randomized, double-blind, placebo-controlled clinical trial
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. No evidence of mitral organic disease
  2. At least moderate left atrial dilatation (left atrial volume index ≥34 mL/m²)
  3. Normal (≥ 50%) and
  4. At least moderate MR grade by multiparametric assessment.

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide
  2. Indication for or ongoing treatment with ACEI/ARB
  3. History of hypotension
  4. Hypertension (>140/90 mmHg) *
  5. Planned cardiac surgery (CABG or valve)
  6. Ongoing or planned pregnancy
  7. Chronic renal failure with \< 30 mL/min/1.73m2
  8. Neurocognitive disorder
  9. History of hyperkalemia
  10. Medication interacting with valsartan
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Valsartan

    Valsartan 40 mg/tablet twice daily. . Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.

    Drug: Valsartan

  • Placebo comparator
    Placebo

    Placebo twice daily

    Drug: Placebo

Interventions

  • Valsartan 40 mg/tablet twice daily vs placebo. Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.

  • DrugPlacebo

    Placebo that looks like valsartan (caps)

06

What researchers measure

Primary outcomes

  1. Mitral leaflet size

    Mitral leaflet size (cm2) by 3D echo and its variation vs baseline.

    Time frame: Baseline VS 12 months

Secondary outcomes

  1. MR progression

    MR progression measured by imaging (3D echocardiography). Mitral regurgitation is graded on a scale of I-IV (grade I (mild MR), grade II (moderate MR), grade III (moderate-to-severe MR) and grade IV (severe MR)). A higher mitral regurgitation grade is generally associated with a worse outcome for the patient.

    Time frame: MR grade at 12 months follow-up vs baseline

  2. Left ventricular volume

    Left ventricular volume (mL) measured by imaging (3D echocardiography)

    Time frame: baseline VS 12 months follow-up

  3. Left ventricular function

    Left ventricular function (% ejection fraction) measured by imaging (3D echocardiography)

    Time frame: baseline VS 12 months follow-up

  4. Pulmonary artery pressure

    Pulmonary artery pressure measured by echocardiography (mmHg).

    Time frame: baseline VS 12 months follow-up

  5. Left atrial volume

    Left atrial volume (ml) measured by echocardiography

    Time frame: Baseline VS 12 months follow-up

  6. Mitral thickness

    Mitral thickness (mm) measured by echocardiography

    Time frame: Baseline VS 12 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for May 2029, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Jul 13, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07539298
Lead sponsor
Jonathan Beaudoin
Collaborators
Fondation IUCPQ, Laval University
Responsible party
Jonathan Beaudoin (MD, Laval University) — Sponsor-investigator
First posted
Apr 20, 2026
Start date
Jul 13, 2026
Primary completion
May 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Aug 20, 2026

Study contacts

Jonathan Beaudoin
Contact
jonathan.beaudoin@criucpq.ulaval.ca
1 (418) 656-8711 ext. 2943
Maude Jolicoeur
Contact
1 (418) 656-8711 ext. 7225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion